Idarucizumab (Praxbind®)

Assessment Status Rapid Review Complete
Drug Idarucizumab
Brand Praxbind®
Indication As a specific reversal agent for dabigatran in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: for emergency surgery/urgent procedures or life-threatening or uncontrolled bleeding.
Assessment Process
Rapid review commissioned 11/12/2015
Rapid review completed 18/12/2015
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended